PALB2 and familial pancreatic carcinoma: Furthermore, the NCCN guidelines also recommended somatic testing of KRAS, BRAF, HER2, PALB2, MMR deficiency, and oncogenic gene fusions for pancreatic cancer patients with advanced or metastatic diseases.2